Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

Fig. 3

Placebo-corrected mean change from baseline in a trough FEV1 at day 2 and b normalized FEV1 AUC0–24 (per protocol population). Data are LS means ± standard error. AUC0–24 = area under the curve from 0 to 24 h post-dose; FEV1 = forced expiratory volume in 1 s; LS = least squares. *P < .0001 vs placebo

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us